Hatake Kiyohiko, Tokudome Nahomi, Ito Yoshinori
Division of Medical Oncology, Cancer Institute Hospital, Tokyo, Japan.
Breast Cancer. 2007;14(2):132-49. doi: 10.2325/jbcs.977.
Here we reviewed the recent progress of molecular targeting drugs, including trastuzumab, lapatinib, erlotinib and bevacituzumab. Fortunately, Her-2 positive cases of metastatic or relapsed cases, those with the worse prognosis, are responsive to trastuzumab-based chemotherapy. Lapatinib will likely be effective against trastuzumab-resistant cases and brain metastases. Furthermore, the introduction of bevacituzumab will improve VEGF-VEGFR- associated tumor growth.
在此，我们回顾了分子靶向药物的近期进展，包括曲妥珠单抗、拉帕替尼、厄洛替尼和贝伐单抗。幸运的是，预后较差的转移性或复发性Her-2阳性病例对基于曲妥珠单抗的化疗有反应。拉帕替尼可能对曲妥珠单抗耐药病例和脑转移有效。此外，贝伐单抗的引入将改善与VEGF-VEGFR相关的肿瘤生长。
